Progyny, Inc. (NASDAQ:PGNY – Get Free Report)’s stock price hit a new 52-week high on Monday . The company traded as high as $28.83 and last traded at $28.3970, with a volume of 313694 shares. The stock had previously closed at $28.51.
Analyst Ratings Changes
PGNY has been the topic of several research reports. Bank of America lifted their price objective on shares of Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Wall Street Zen raised shares of Progyny from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Citigroup restated an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. Barclays lifted their price target on shares of Progyny from $23.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Finally, KeyCorp reduced their target price on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Eleven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.92.
View Our Latest Stock Report on PGNY
Progyny Stock Performance
Progyny (NASDAQ:PGNY – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. The company had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.46 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm’s revenue was down 26.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, analysts anticipate that Progyny, Inc. will post 1.07 EPS for the current year.
Progyny announced that its board has authorized a share repurchase plan on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to buy up to 10.3% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.
Insider Activity at Progyny
In related news, CFO Mark S. Livingston sold 2,517 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $25.50, for a total transaction of $64,183.50. Following the transaction, the chief financial officer directly owned 74,688 shares in the company, valued at $1,904,544. This trade represents a 3.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Scott sold 7,439 shares of Progyny stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $26.39, for a total value of $196,315.21. Following the completion of the transaction, the director directly owned 19,772 shares in the company, valued at $521,783.08. This trade represents a 27.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,916 shares of company stock worth $939,875 over the last three months. Corporate insiders own 9.90% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP grew its holdings in Progyny by 260.9% in the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after acquiring an additional 1,621,688 shares during the last quarter. Fort Washington Investment Advisors Inc. OH raised its stake in shares of Progyny by 46.9% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after acquiring an additional 859,289 shares during the last quarter. Loomis Sayles & Co. L P bought a new stake in shares of Progyny in the fourth quarter worth about $19,917,000. Barclays PLC grew its stake in shares of Progyny by 79.2% in the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after purchasing an additional 696,447 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Progyny by 37.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after purchasing an additional 545,431 shares during the period. 94.93% of the stock is owned by hedge funds and other institutional investors.
Progyny Company Profile
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Read More
- Five stocks we like better than Progyny
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
